A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

NCT03781219 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: HL-085
DRUG: Vemurafenib

Sponsor

Shanghai Kechow Pharma, Inc.